Dev Labtech Venture Ltd (543848)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Dev Labtech's revenue was ₹118 Cr (+257.6% year on year, +140.8% on the previous half-year), and net profit ₹9.0 Cr (+800.0% year on year); the operating margin was 8.5%.
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹118 | +257.6% | +140.8% |
| Operating profit | ₹10.0 | +400.0% | +900.0% |
| Net profit | ₹9.0 | +800.0% | — |
| EPS (₹) | 1.95 | — | — |
| Operating margin | 8.5% | — | — |
No EPS growth against H1 FY26 and H2 FY25: ₹10 to ₹5 split in May 2026 and 1:1 bonus in May 2026.
📢 Recent Corporate Announcements
Dev Labtech Venture Limited has issued an EGM notice for November 5, 2026, to approve a preferential issue of up to 1.37 crore convertible warrants at ₹13 each, aggregating to ₹17.81 crore. The warrants will be allotted to promoter and non-promoter entities, with promoters receiving 1.08 crore warrants. The fundraise represents approximately 22% of the company's current market cap of ₹81 crore and 40.5% of its net worth (₹44 crore). Additionally, the company seeks shareholder approval to increase its authorized share capital from ₹25 crore to ₹31 crore.
- Proposed preferential issue of 1,37,00,000 convertible warrants at ₹13 per warrant aggregating to ₹17.81 crore
- Issue price of ₹13 represents a discount to the current market price of ₹18.7
- Promoters/Promoter Group to be allocated 1,07,92,000 warrants (78.8% of the issue)
- Authorized share capital proposed to increase from ₹25.00 crore to ₹31.00 crore
- EGM scheduled for Thursday, November 5, 2026 at 1:00 PM via VC/OAVM
Dev Labtech Venture Ltd's board approved the preferential issuance of up to 1.37 crore convertible warrants at ₹13 per warrant, aggregating to ₹17.81 crore. The warrants are being issued to promoters and non-promoter investors, with promoter holding slated to rise to 61.64% from 56.69% post-conversion. The warrant price of ₹13 represents a discount to the current market price of ₹18.7. To facilitate this, the board also approved increasing the authorized share capital from ₹25 crore to ₹31 crore, subject to shareholder approval at an EGM on November 5, 2026.
- Issuance of up to 1,37,00,000 convertible warrants at ₹13 each (aggregating ₹17,81,00,000)
- Post-conversion promoter shareholding will increase to 61.64% (from 56.69%), while non-promoters will hold 38.36%
- Authorized share capital increased from ₹25,00,00,000 (5 crore shares) to ₹31,00,00,000 (6.2 crore shares)
- Warrant tenor is 18 months, exercisable into equity shares of face value ₹5 at a ₹8 premium
- EGM scheduled for November 5, 2026 with a voting cut-off date of October 29, 2026
Dev Labtech Venture Ltd's board approved the preferential issuance of up to 1.37 crore convertible warrants at ₹13 per warrant, aggregating to ₹17.81 crore. The warrants are being issued to promoters and non-promoter investors, with promoter holding slated to rise to 61.64% from 56.69% post-conversion. The warrant price of ₹13 represents a discount to the current market price of ₹18.7. To facilitate this, the board also approved increasing the authorized share capital from ₹25 crore to ₹31 crore, subject to shareholder approval at an EGM on November 5, 2026.
- Issuance of up to 1,37,00,000 convertible warrants at ₹13 each (aggregating ₹17,81,00,000)
- Post-conversion promoter shareholding will increase to 61.64% (from 56.69%), while non-promoters will hold 38.36%
- Authorized share capital increased from ₹25,00,00,000 (5 crore shares) to ₹31,00,00,000 (6.2 crore shares)
- Warrant tenor is 18 months, exercisable into equity shares of face value ₹5 at a ₹8 premium
- EGM scheduled for November 5, 2026 with a voting cut-off date of October 29, 2026
Dev Labtech Venture Ltd's board approved the preferential issuance of up to 1.37 crore convertible warrants at ₹13 per warrant, aggregating to ₹17.81 crore. The warrants are being issued to promoters and non-promoter investors, with promoter holding slated to rise to 61.64% from 56.69% post-conversion. The warrant price of ₹13 represents a discount to the current market price of ₹18.7. To facilitate this, the board also approved increasing the authorized share capital from ₹25 crore to ₹31 crore, subject to shareholder approval at an EGM on November 5, 2026.
- Issuance of up to 1,37,00,000 convertible warrants at ₹13 each (aggregating ₹17,81,00,000)
- Post-conversion promoter shareholding will increase to 61.64% (from 56.69%), while non-promoters will hold 38.36%
- Authorized share capital increased from ₹25,00,00,000 (5 crore shares) to ₹31,00,00,000 (6.2 crore shares)
- Warrant tenor is 18 months, exercisable into equity shares of face value ₹5 at a ₹8 premium
- EGM scheduled for November 5, 2026 with a voting cut-off date of October 29, 2026
Dev Labtech Venture Ltd's board approved the preferential issuance of up to 1.37 crore convertible warrants at ₹13 per warrant, aggregating to ₹17.81 crore. The warrants are being issued to promoters and non-promoter investors, with promoter holding slated to rise to 61.64% from 56.69% post-conversion. The warrant price of ₹13 represents a discount to the current market price of ₹18.7. To facilitate this, the board also approved increasing the authorized share capital from ₹25 crore to ₹31 crore, subject to shareholder approval at an EGM on November 5, 2026.
- Issuance of up to 1,37,00,000 convertible warrants at ₹13 each (aggregating ₹17,81,00,000)
- Post-conversion promoter shareholding will increase to 61.64% (from 56.69%), while non-promoters will hold 38.36%
- Authorized share capital increased from ₹25,00,00,000 (5 crore shares) to ₹31,00,00,000 (6.2 crore shares)
- Warrant tenor is 18 months, exercisable into equity shares of face value ₹5 at a ₹8 premium
- EGM scheduled for November 5, 2026 with a voting cut-off date of October 29, 2026
Dev Labtech Venture Ltd has scheduled a Board of Directors meeting on October 7, 2026, to evaluate proposals for raising funds via preferential allotment of equity shares or convertible securities. The board will also consider an increase in the company's authorized share capital. With a current market capitalization of ₹81 Cr, any significant preferential issue could lead to meaningful equity dilution. Trading window for insiders has been closed effective October 2, 2026.
- Board meeting scheduled for October 7, 2026, at 3:00 PM
- Proposal to increase authorized share capital under consideration
- Evaluation of fundraise via preferential issue of equity shares or convertible securities
- Insider trading window closed from October 2, 2026 until 48 hours post announcement
Dev Labtech Venture Limited has announced the outcome of its Board Meeting held on August 27, 2026. The Board approved the Directors' Report for the financial year ended March 31, 2026. Additionally, the 33rd Annual General Meeting (AGM) has been scheduled for September 26, 2026, via Video Conferencing. The cut-off date to determine eligibility for e-voting has been fixed as September 19, 2026.
- 33rd Annual General Meeting (AGM) scheduled for September 26, 2026, at 01:00 p.m. via VC/OAVM.
- Cut-off date for e-voting eligibility fixed as Saturday, September 19, 2026.
- Appointed NSDL to provide the e-voting platform.
- Appointed Mr. Ricky Kapadia (RPK & Associates) as the scrutinizer for voting processes.
Dev Labtech Venture Ltd has approved availing a ₹2.10 crore credit facility from HDFC Bank to support its operations. This facility is relatively small, representing approximately 1.9% of its TTM revenue of ₹112 crore. Additionally, the board has reversed its January 2026 decision to strike off its US-based wholly-owned subsidiary, Dev Labtech Venture Inc., citing new strategic expansion plans. This pivot suggests a renewed focus on international markets despite the company's thin TTM PAT of ₹1 crore.
- Approved a new credit facility of ₹2.10 crore from HDFC Bank.
- Withdrew the voluntary strike-off proposal for US subsidiary Dev Labtech Venture Inc. originally dated January 22, 2026.
- The credit facility represents ~4.8% of the company's current net worth of ₹44 crore.
- The company reported a significant revenue drop in Mar 2026 (₹10.05 cr) compared to Sep 2025 (₹49.24 cr).
- Management states the retention of the US arm will not have a material adverse impact on financials.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
